William Plovanic
Stock Analyst at Canaccord Genuity
(3.10)
# 1,177
Out of 5,141 analysts
176
Total ratings
40.51%
Success rate
2.31%
Average return
Main Sectors:
Stocks Rated by William Plovanic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRTC iRhythm Holdings | Maintains: Buy | $212 → $198 | $150.96 | +31.16% | 14 | Feb 20, 2026 | |
| PODD Insulet | Maintains: Buy | $450 → $435 | $241.89 | +79.83% | 8 | Feb 19, 2026 | |
| ATRC AtriCure | Maintains: Buy | $64 → $53 | $32.58 | +62.68% | 13 | Feb 18, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $112 → $109 | $74.58 | +46.15% | 15 | Feb 17, 2026 | |
| DXCM DexCom | Maintains: Buy | $99 → $95 | $73.08 | +29.99% | 10 | Feb 13, 2026 | |
| CVRX CVRx, Inc. | Maintains: Buy | $11 → $10 | $6.11 | +63.67% | 10 | Feb 13, 2026 | |
| AORT Artivion | Maintains: Buy | $51 → $48 | $38.33 | +25.23% | 5 | Feb 13, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $24 → $35 | $24.57 | +42.45% | 7 | Dec 17, 2025 | |
| TMDX TransMedics Group | Maintains: Buy | $147 → $148 | $134.25 | +10.24% | 9 | Dec 17, 2025 | |
| TLSI TriSalus Life Sciences | Maintains: Buy | $11 → $12 | $5.45 | +120.18% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $89 → $87 | $79.78 | +9.05% | 30 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $30 | $20.22 | +48.37% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $40 | $25.10 | +59.36% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $18 | $11.22 | +60.43% | 8 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.29 | +442.64% | 4 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $97 → $90 | $90.59 | -0.65% | 4 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $115 → $101 | $98.75 | +2.28% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $15 | $8.58 | +74.83% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $284 | $339.36 | -16.31% | 4 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $25 | $13.01 | +92.16% | 1 | Jan 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $12 | $1.51 | +697.34% | 5 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $86 → $70 | $82.21 | -14.85% | 4 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $77 → $48 | $17.76 | +170.27% | 5 | Aug 3, 2023 |
iRhythm Holdings
Feb 20, 2026
Maintains: Buy
Price Target: $212 → $198
Current: $150.96
Upside: +31.16%
Insulet
Feb 19, 2026
Maintains: Buy
Price Target: $450 → $435
Current: $241.89
Upside: +79.83%
AtriCure
Feb 18, 2026
Maintains: Buy
Price Target: $64 → $53
Current: $32.58
Upside: +62.68%
Boston Scientific
Feb 17, 2026
Maintains: Buy
Price Target: $112 → $109
Current: $74.58
Upside: +46.15%
DexCom
Feb 13, 2026
Maintains: Buy
Price Target: $99 → $95
Current: $73.08
Upside: +29.99%
CVRx, Inc.
Feb 13, 2026
Maintains: Buy
Price Target: $11 → $10
Current: $6.11
Upside: +63.67%
Artivion
Feb 13, 2026
Maintains: Buy
Price Target: $51 → $48
Current: $38.33
Upside: +25.23%
Tandem Diabetes Care
Dec 17, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $24.57
Upside: +42.45%
TransMedics Group
Dec 17, 2025
Maintains: Buy
Price Target: $147 → $148
Current: $134.25
Upside: +10.24%
TriSalus Life Sciences
Dec 17, 2025
Maintains: Buy
Price Target: $11 → $12
Current: $5.45
Upside: +120.18%
Dec 17, 2025
Maintains: Hold
Price Target: $89 → $87
Current: $79.78
Upside: +9.05%
Dec 17, 2025
Maintains: Buy
Price Target: $29 → $30
Current: $20.22
Upside: +48.37%
Nov 13, 2025
Maintains: Buy
Price Target: $39 → $40
Current: $25.10
Upside: +59.36%
Oct 3, 2025
Maintains: Buy
Price Target: $17 → $18
Current: $11.22
Upside: +60.43%
Aug 6, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $1.29
Upside: +442.64%
Jul 22, 2025
Maintains: Buy
Price Target: $97 → $90
Current: $90.59
Upside: -0.65%
May 12, 2025
Maintains: Hold
Price Target: $115 → $101
Current: $98.75
Upside: +2.28%
Nov 6, 2024
Maintains: Buy
Price Target: $12 → $15
Current: $8.58
Upside: +74.83%
Feb 23, 2024
Reiterates: Buy
Price Target: $284
Current: $339.36
Upside: -16.31%
Jan 22, 2024
Maintains: Buy
Price Target: $22 → $25
Current: $13.01
Upside: +92.16%
Oct 31, 2023
Maintains: Buy
Price Target: $20 → $12
Current: $1.51
Upside: +697.34%
Aug 28, 2023
Maintains: Hold
Price Target: $86 → $70
Current: $82.21
Upside: -14.85%
Aug 3, 2023
Downgrades: Hold
Price Target: $77 → $48
Current: $17.76
Upside: +170.27%